Citation: | ZHOU Xirui, GU Renji, MA Ruimin, JIANG Wencan, LUO Shizhong, FENG Liuxing. Advances in Measurement Techniques and Standardization of Alzheimer's Disease Biomarkers[J]. Metrology Science and Technology, 2024, 68(9): 41-50. doi: 10.12338/j.issn.2096-9015.2024.0054 |
[1] |
JACK C R, ALBERT M S, KNOPMAN D S, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease[J]. Alzheimer’s & Dementia, 2011, 7(3): 257-262.
|
[2] |
DUBOIS B, FELDMAN H H, JACOVA C, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria[J]. The Lancet Neurology, 2014, 13(6): 614-629. doi: 10.1016/S1474-4422(14)70090-0
|
[3] |
JACK C R, BENNETT D A, BLENNOW K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease[J]. Alzheimer’s Dement, 2018, 14(4): 535-562. doi: 10.1016/j.jalz.2018.02.018
|
[4] |
DHAPOLA R, HOTA S S, SARMA P, et al. Recent advances in molecular pathways and therapeutic implications targeting neuroinflammation for Alzheimer’s disease[J]. Inflammopharmacology, 2021, 29(6): 1669-1681. doi: 10.1007/s10787-021-00889-6
|
[5] |
LAFERLA F M, GREEN K N, ODDO S. Intracellular amyloid-β in Alzheimer’s disease[J]. Nature Reviews Neuroscience, 2007, 8(7): 499-509. doi: 10.1038/nrn2168
|
[6] |
VERMA A, KUMAR WAIKER D, BHARDWAJ B, et al. The molecular mechanism, targets, and novel molecules in the treatment of Alzheimer’s disease[J]. Bioorganic Chemistry, 2022, 119: 105562. doi: 10.1016/j.bioorg.2021.105562
|
[7] |
SEUBERT P, OLTERSDORF T, LEE M G, et al. Secretion of β-amyloid precursor protein cleaved at the amino terminus of the β-amyloid peptide[J]. Nature, 1993, 361(6409): 260-263. doi: 10.1038/361260a0
|
[8] |
HAASS C, SCHLOSSMACHER M G, HUNG A Y, et al. Amyloid β-peptide is produced by cultured cells during normal metabolism[J]. Nature, 1992, 359(6393): 322-325. doi: 10.1038/359322a0
|
[9] |
CHEN G F, XU T H, YAN Y, et al. Amyloid beta: structure, biology and structure-based therapeutic development[J]. Acta Pharmacologica Sinica, 2017, 38(9): 1205-1235. doi: 10.1038/aps.2017.28
|
[10] |
BLENNOW K, DE LEON M J, ZETTERBERG H. Alzheimer’s disease[J]. The Lancet, 2006, 368(9533): 387-403. doi: 10.1016/S0140-6736(06)69113-7
|
[11] |
MASTERS C L, SIMMS G, WEINMAN N A, et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome[J]. Proceedings of the National Academy of Sciences, 1985, 82(12): 4245-4249. doi: 10.1073/pnas.82.12.4245
|
[12] |
LEHMANN S, DUMURGIER J, AYRIGNAC X, et al. Cerebrospinal fluid A beta 1–40 peptides increase in Alzheimer’s disease and are highly correlated with phospho-tau in control individuals[J]. Alzheimer’s Research & Therapy, 2020, 12(1): 123.
|
[13] |
BLENNOW K, DUBOIS B, FAGAN A M, et al. Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer’s disease[J]. Alzheimer’s & Dementia, 2015, 11(1): 58-69.
|
[14] |
SHAW L M, KORECKA M, CLARK C M, et al. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics[J]. Nature Reviews Drug Discovery, 2007, 6(4): 295-303. doi: 10.1038/nrd2176
|
[15] |
BENZINGER T L S, BLAZEY T, JACK C R, et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease[J]. Proceedings of the National Academy of Sciences, 2013, 110(47): E4502-E4509.
|
[16] |
TEUNISSEN C E, VERBERK I M W, THIJSSEN E H, et al. Blood-based biomarkers for Alzheimer’s disease: towards clinical implementation[J]. The Lancet Neurology, 2022, 21(1): 66-77. doi: 10.1016/S1474-4422(21)00361-6
|
[17] |
BILGEL M, AN Y, WALKER K A, et al. Longitudinal changes in Alzheimer’s-related plasma biomarkers and brain amyloid[J]. Alzheimer’s & Dementia, 2023, 19(10): 4335-4345.
|
[18] |
AMFT M, ORTNER M, EICHENLAUB U, et al. The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort[J]. Alzheimer’s Research & Therapy, 2022, 14(1): 60.
|
[19] |
WEINGARTEN M D, LOCKWOOD A H, HWO S Y, et al. A protein factor essential for microtubule assembly[J]. Proceedings of the National Academy of Sciences, 1975, 72(5): 1858-1862. doi: 10.1073/pnas.72.5.1858
|
[20] |
WANG Y, MANDELKOW E. Tau in physiology and pathology[J]. Nature Reviews Neuroscience, 2016, 17(1): 22-35. doi: 10.1038/nrn.2015.1
|
[21] |
DIXIT R, ROSS J L, GOLDMAN Y E, et al. Differential regulation of dynein and kinesin motor proteins by tau[J]. Science, 2008, 319: 1086-1089. doi: 10.1126/science.1152993
|
[22] |
HANGER D P, ANDERTON B H, NOBLE W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease[J]. Trends Mol Med, 2009, 15(3): 112-119. doi: 10.1016/j.molmed.2009.01.003
|
[23] |
MARTIN L, LATYPOVA X, TERRO F. Post-translational modifications of tau protein: implications for Alzheimer’s disease[J]. Neurochem Int, 2011, 58(4): 458-471. doi: 10.1016/j.neuint.2010.12.023
|
[24] |
MIELKE M M, DAGE J L, FRANK R D, et al. Performance of plasma phosphorylated tau 181 and 217 in the community[J]. Nature Medicine, 2022, 28(7): 1398-1405. doi: 10.1038/s41591-022-01822-2
|
[25] |
PALMQVIST S, JANELIDZE S, QUIROZ Y T, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer Disease vs other neurodegenerative disorders[J]. JAMA, 2020, 324(8): 772-781. doi: 10.1001/jama.2020.12134
|
[26] |
ISHIKAWA H, BISCHOFF R, HOLTZER H. Mitosis and intermediate-sized filaments in developing skeletal muscle[J]. The Journal of Cell Biology, 1968, 38(3): 538-555. doi: 10.1083/jcb.38.3.538
|
[27] |
PETZOLD A. Neurofilament phosphoforms: Surrogate markers for axonal injury, degeneration and loss[J]. Journal of the Neurological Sciences, 2005, 233(1-2): 183-198. doi: 10.1016/j.jns.2005.03.015
|
[28] |
Lépinoux-Chambaud C, Eyer J. Review on intermediate filaments of the nervous system and their pathological alterations[J]. Histochemistry Cell Biology, 2013, 140(1): 13-22. doi: 10.1007/s00418-013-1101-1
|
[29] |
KUHLE J, GAIOTTINO J, LEPPERT D, et al. Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome[J]. J Neurol Neurosurg Psychiatry, 2015, 86(3): 273-279. doi: 10.1136/jnnp-2013-307454
|
[30] |
LU C H, Macdonald-Wallis C, Gray E, et al. Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis[J]. Neurology, 2015, 84(22): 2247-2257. doi: 10.1212/WNL.0000000000001642
|
[31] |
Bäckström DC, Eriksson Domellöf M, Linder J, et al. Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease[J]. JAMA Neurology, 2015, 72(10): 1175-1182. doi: 10.1001/jamaneurol.2015.1449
|
[32] |
SCHERLING C S, HALL T, BERISHA F, et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration[J]. Annals of Neurology, 2014, 75(1): 116-126. doi: 10.1002/ana.24052
|
[33] |
ZETTERBERG H, SKILLBäCK T, MATTSSON N, et al. Association of cerebrospinal fluid neurofilament light concentration with Alzheimer Disease progression[J]. JAMA Neurology, 2016, 73(1): 60-67. doi: 10.1001/jamaneurol.2015.3037
|
[34] |
BACIOGLU M, MAIA L F, PREISCHE O, et al. Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases[J]. Neuron, 2016, 91(1): 56-66. doi: 10.1016/j.neuron.2016.05.018
|
[35] |
BRUREAU A, BLANCHARD-BREGEON V, PECH C, et al. NF-L in cerebrospinal fluid and serum is a biomarker of neuronal damage in an inducible mouse model of neurodegeneration[J]. Neurobiology of Disease, 2017, 104: 73-84. doi: 10.1016/j.nbd.2017.04.007
|
[36] |
WESTON P S J, POOLE T, RYAN N S, et al. Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration[J]. Neurology, 2017, 89(21): 2167-2175. doi: 10.1212/WNL.0000000000004667
|
[37] |
PREISCHE O, SCHULTZ S A, APEL A, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease[J]. Nature Medicine, 2019, 25(2): 277-283. doi: 10.1038/s41591-018-0304-3
|
[38] |
BRAUNEWELL K H, SZANTO A J K. Visinin-like proteins (VSNLs): interaction partners and emerging functions in signal transduction of a subfamily of neuronal Ca2+-sensor proteins[J]. Cell and Tissue Research, 2009, 335(2): 301-316. doi: 10.1007/s00441-008-0716-3
|
[39] |
BURGOYNE R D. Neuronal calcium sensor proteins: generating diversity in neuronal Ca2+ signaling[J]. Nature Reviews Neuroscience, 2007, 8(3): 182-193. doi: 10.1038/nrn2093
|
[40] |
TAN Z, JIANG J, TIAN F, et al. Serum visinin-like protein 1 is a better biomarker than neuron-specific enolase for seizure-induced neuronal injury: a prospective and observational study[J]. Frontiers in Neurology, 2020, 11: 567587. doi: 10.3389/fneur.2020.567587
|
[41] |
TARAWNEH R, LEE J M, LADENSON J H, et al. CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease[J]. Neurology, 2012, 78(10): 709-719. doi: 10.1212/WNL.0b013e318248e568
|
[42] |
HALBGEBAUER S, STEINACKER P, RIEDEL D, et al. Visinin-like protein 1 levels in blood and CSF as emerging markers for Alzheimer’s and other neurodegenerative diseases[J]. Alzheimer’s Research & Therapy, 2022, 14(1): 175.
|
[43] |
GROBLEWSKA M, MUSZYŃSKI P, WOJTULEWSKA-SUPRON A, et al. The Role of Visinin-Like Protein-1 in the Pathophysiology of Alzheimer’s Disease[J]. J Alzheimers Dis, 2015, 47(1): 17-32. doi: 10.3233/JAD-150060
|
[44] |
MOTTER R, VIGO-PELFREY C, KHOLODENKO D, et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer’s disease[J]. Annals of Neurology, 1995, 38(4): 643-648. doi: 10.1002/ana.410380413
|
[45] |
VANMECHELEN E, VANDERSTICHELE H, DAVIDSSON P, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization[J]. Neuroscience Letters, 2000, 285(1): 49-52. doi: 10.1016/S0304-3940(00)01036-3
|
[46] |
BITTNER T, ZETTERBERG H, TEUNISSEN C E, et al. Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1–42) in human cerebrospinal fluid[J]. Alzheimer’s & Dementia, 2016, 12(5): 517-526.
|
[47] |
LIFKE V, KOLLMORGEN G, MANUILOVA E, et al. Elecsys® Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid[J]. Clinical Biochemistry, 2019, 72: 30-38. doi: 10.1016/j.clinbiochem.2019.05.005
|
[48] |
BAYART J, HANSEEUW B, IVANOIU A, et al. Analytical and clinical performances of the automated Lumipulse cerebrospinal fluid A beta(42) and T-Tau assays for Alzheimer’s disease diagnosis[J]. Journal of neurology, 2019, 266(9): 2304-2311. doi: 10.1007/s00415-019-09418-6
|
[49] |
GORDON R F, MCDADE R L. Multiplexed quantification of human IgG, IgA, and IgM with the FlowMetrix system[J]. Clin Chem, 1997, 43(9): 1799-1801. doi: 10.1093/clinchem/43.9.1799
|
[50] |
PRABHAKAR U, EIRIKIS E, DAVIS H M. Simultaneous quantification of proinflammatory cytokines in human plasma using the LabMAP assay[J]. J Immunol Methods, 2002, 260(1-2): 207-218. doi: 10.1016/S0022-1759(01)00543-9
|
[51] |
OLSSON A, VANDERSTICHELE H, ANDREASEN N, et al. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology[J]. Clin Chem, 2005, 51(2): 336-345. doi: 10.1373/clinchem.2004.039347
|
[52] |
REIJN T S, RIKKERT MO, VAN GEEL W J A, et al. Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid beta(42) and tau proteins[J]. Clin Chem, 2007, 53(5): 859-865. doi: 10.1373/clinchem.2006.081679
|
[53] |
WEISSLEDER R. Molecular imaging: exploring the next frontier[J]. Radiology, 1999, 212(3): 609-614. doi: 10.1148/radiology.212.3.r99se18609
|
[54] |
GORDON B A, BLAZEY T M, SU Y, et al. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer’s disease: a longitudinal study[J]. Lancet Neurol, 2018, 17(3): 241-250. doi: 10.1016/S1474-4422(18)30028-0
|
[55] |
VILLEMAGNE V L, BURNHAM S, BOURGEAT P, et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study[J]. Lancet Neurology, 2013, 12(4): 357-367. doi: 10.1016/S1474-4422(13)70044-9
|
[56] |
Pemberton HG, Collij LE, Heeman F, et al. Quantification of amyloid PET for future clinical use: a state-of-the-art review[J]. Eur J Nucl Med Mol Imaging, 2022, 49(10): 3508-3528. doi: 10.1007/s00259-022-05784-y
|
[57] |
TIAN M, ZUO C, CIVELEK A C, et al. International nuclear medicine consensus on the clinical use of amyloid positron emission tomography in Alzheimer’s Disease[J]. Phenomics, 2023, 3(4): 375-389. doi: 10.1007/s43657-022-00068-9
|
[58] |
SCHöLL M, MAASS A, MATTSSON N, et al. Biomarkers for tau pathology[J]. Molecular and Cellular Neuroscience, 2019, 97: 18-33. doi: 10.1016/j.mcn.2018.12.001
|
[59] |
TIAN M, CIVELEK A C, CARRIO I, et al. International consensus on the use of tau PET imaging agent (18)F-flortaucipir in Alzheimer’s disease[J]. Eur J Nucl Med Mol Imaging, 2022, 49(3): 895-904. doi: 10.1007/s00259-021-05673-w
|
[60] |
RISSIN D M, KAN C W, CAMPBELL T G, et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations[J]. Nature Biotechnology, 2010, 28(6): 595-599. doi: 10.1038/nbt.1641
|
[61] |
COHEN L, CUI N, CAI Y, et al. Single molecule protein detection with attomolar sensitivity using droplet digital enzyme-linked immunosorbent assay[J]. ACS Nano, 2020, 14(8): 9491-9501. doi: 10.1021/acsnano.0c02378
|
[62] |
WANG D, WANG X, YE F, et al. An integrated amplification-free digital crispr/cas-assisted assay for single molecule detection of RNA[J]. ACS Nano, 2023, 17(8): 7250-7256. doi: 10.1021/acsnano.2c10143
|
[63] |
REN M, DONG Y, WANG J, et al. Computer vision-assisted smartphone microscope imaging digital immunosensor based on click chemistry-mediated microsphere counting technology for the detection of aflatoxin B1 in peanuts[J]. Analytica Chimica Acta, 2023, 1278: 341687. doi: 10.1016/j.aca.2023.341687
|
[64] |
LEIRS K, DAL DOSSO F, PEREZ-RUIZ E, et al. Bridging the Gap between digital assays and point-of-care testing: automated, low cost, and ultrasensitive detection of thyroid stimulating hormone[J]. Analytical Chemistry, 2022, 94(25): 8919-8927. doi: 10.1021/acs.analchem.2c00480
|
[65] |
SHI Y, LU X, ZHANG L, et al. Potential value of plasma amyloid-β, total tau, and neurofilament light for identification of early Alzheimer’s disease[J]. ACS Chemical Neuroscience, 2019, 10(8): 3479-3485. doi: 10.1021/acschemneuro.9b00095
|
[66] |
NI M, ZHU Z H, GAO F, et al. Plasma core alzheimer’s disease biomarkers predict amyloid deposition burden by positron emission tomography in chinese individuals with cognitive decline[J]. ACS Chemical Neuroscience, 2023, 14(1): 170-179. doi: 10.1021/acschemneuro.2c00636
|
[67] |
XIE Q, NI M, GAO F, et al. Correlation between cerebrospinal fluid core Alzheimer’s disease biomarkers and β-amyloid PET in Chinese dementia population[J]. ACS Chemical Neuroscience, 2022, 13(10): 1558-1565. doi: 10.1021/acschemneuro.2c00120
|
[68] |
SEINO Y, NAKAMURA T, HARADA T, et al. Quantitative measurement of cerebrospinal fluid amyloid-β species by mass spectrometry[J]. Journal of Alzheimer’s Disease, 2021, 79: 573-584. doi: 10.3233/JAD-200987
|
[69] |
ZOU Y, MA X, MAO C, et al. Automated magnetic-bead-assisted sequential extraction technology for simultaneous detection of Aβ1-42 and Aβ1-40 in cerebrospinal fluid: An advance toward fully automated liquid chromatography-tandem mass spectrometry method[J]. Journal of Chromatography A, 2024, 1713: 1.
|
[70] |
LEINENBACH A, PANNEE J, DüLFFER T, et al. Mass spectrometry–based candidate reference measurement procedure for quantification of amyloid-β in cerebrospinal fluid[J]. Clinical Chemistry, 2014, 60(7): 987-994. doi: 10.1373/clinchem.2013.220392
|
[71] |
MCAVOY T, LASSMAN M E, SPELLMAN D S, et al. Quantification of tau in cerebrospinal fluid by immunoaffinity enrichment and tandem mass spectrometry[J]. Clinical Chemistry, 2014, 60(4): 683-689. doi: 10.1373/clinchem.2013.216515
|
[72] |
BROS P, VIALARET J, BARTHELEMY N, et al. Antibody-free quantification of seven tau peptides in human CSF using targeted mass spectrometry[J]. Front Neurosci, 2015, 9: 302.
|
[73] |
BJERKE M, ANDREASSON U, KUHLMANN J, et al. Assessing the commutability of reference material formats for the harmonization of amyloid-β measurements[J]. Clin Chem Lab Med, 2016, 54(7): 1177-1191. doi: 10.1515/cclm-2015-0733
|
[74] |
LAME M E, CHAMBERS E E, BLATNIK M. Quantitation of amyloid beta peptides Aβ(1-38), Aβ(1-40), and Aβ(1-42) in human cerebrospinal fluid by ultra-performance liquid chromatography-tandem mass spectrometry[J]. Analytical biochemistry, 2011, 419(2): 133-139. doi: 10.1016/j.ab.2011.08.010
|
[75] |
PANNEE J, PORTELIUS E, MINTHON L, et al. Reference measurement procedure for CSF amyloid beta (Aβ)1–42 and the CSF Aβ1–42/Aβ1–40 ratio-a cross-validation study against amyloid PET[J]. Journal of Neurochemistry, 2016, 139(4): 651-658. doi: 10.1111/jnc.13838
|
[76] |
KORECKA M, FIGURSKI M J, LANDAU S M, et al. Analytical and clinical performance of amyloid-beta peptides measurements in CSF of ADNIGO/2 participants by an LC–MS/MS reference method[J]. Clinical Chemistry, 2020, 66(4): 587-597. doi: 10.1093/clinchem/hvaa012
|
[77] |
ZOU Y, MA X, MAO C, et al. Automated magnetic-bead-assisted sequential extraction technology for simultaneous detection of Aβ1-42 and Aβ1-40 in cerebrospinal fluid: An advance toward fully automated liquid chromatography-tandem mass spectrometry method[J]. Journal of Chromatogrraphy A, 2024, 1713: 464531. doi: 10.1016/j.chroma.2023.464531
|
[78] |
FENG L, HUO Z, XIONG J, et al. Certification of amyloid-beta (aβ) certified reference materials by amino acid-based isotope dilution high-performance liquid chromatography mass spectrometry and sulfur-based high-performance liquid chromatography isotope dilution inductively coupled plasma mass spectrometry[J]. Analytical Chemistry, 2020, 92(19): 13229-13237. doi: 10.1021/acs.analchem.0c02381
|
[79] |
BOULO S, KUHLMANN J, ANDREASSON U, et al. First amyloid β1-42 certified reference material for re-calibrating commercial immunoassays[J]. Alzheimer’s & Dementia, 2020, 16(11): 1493-1503.
|
[80] |
GIANGRANDE C, VANEECKHOUTTE H, BOEUF A, et al. Development of a candidate reference measurement procedure by ID-LC-MS/MS for total tau protein measurement in cerebrospinal fluid (CSF)[J]. Clin Chem Lab Med, 2023, 61(7): 1235-1244. doi: 10.1515/cclm-2022-1250
|
[81] |
ZANG Y, ZHOU X, PAN M, et al. Certification of visinin-like protein-1 (VILIP-1) certified reference material by amino acid-based and sulfur-based liquid chromatography isotope dilution mass spectrometry[J]. Analytical and Bioanalytical Chemistry, 2023, 415(1): 211-220. doi: 10.1007/s00216-022-04401-z
|